# Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

> **NCT01026233** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 52 (actual)

## Conditions studied

- Disease, Hodgkin
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** brentuximab vedotin

## Key facts

- **NCT ID:** NCT01026233
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-08
- **Final completion:** 2011-08
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2014-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01026233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01026233, "Cardiac Safety Study of Brentuximab Vedotin (SGN-35)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01026233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*